174 related articles for article (PubMed ID: 4038390)
1. Clinical pharmacology of intraperitoneal cisplatin.
Lopez JA; Krikorian JG; Reich SD; Smyth RD; Lee FH; Issell BF
Gynecol Oncol; 1985 Jan; 20(1):1-9. PubMed ID: 4038390
[TBL] [Abstract][Full Text] [Related]
2. Ip cisplatin in patients with malignant ascites: pharmacokinetic evaluation and comparison with the iv route.
Casper ES; Kelsen DP; Alcock NW; Lewis JL
Cancer Treat Rep; 1983 Mar; 67(3):235-8. PubMed ID: 6682012
[TBL] [Abstract][Full Text] [Related]
3. [Pharmacokinetics study of intraperitoneal cisplatin in ovarian carcinoma].
Han GR; Cai GF
Zhonghua Fu Chan Ke Za Zhi; 1993 Apr; 28(4):224-6, 254. PubMed ID: 8404307
[TBL] [Abstract][Full Text] [Related]
4. High doses of intrapleural cisplatin in a case of malignant pleural mesothelioma. Clinical observations and pharmacokinetic analyses.
Lerza R; Esposito M; Vannozzi M; Bottino GB; Bogliolo G; Pannacciulli I
Cancer; 1994 Jan; 73(1):79-84. PubMed ID: 8275441
[TBL] [Abstract][Full Text] [Related]
5. Regional pharmacokinetic selectivity of intraperitoneal cisplatin in ovarian cancer.
Esposito M; Campora E; Repetto M; Fulco RA; Simoni GA; Falcone A; Collecchi P; Gogioso L; Nobile MT; Civalleri D
Oncology; 1988; 45(2):69-73. PubMed ID: 3353075
[TBL] [Abstract][Full Text] [Related]
6. Kinetics of cis-dichlorodiammineplatinum.
Gormley PE; Bull JM; LeRoy AF; Cysyk R
Clin Pharmacol Ther; 1979 Mar; 25(3):351-7. PubMed ID: 761445
[TBL] [Abstract][Full Text] [Related]
7. Disposition of total and free cisplatin on two consecutive treatment cycles in patients with ovarian cancer.
Erlichman C; Soldin SJ; Thiessen JJ; Sturgeon JF; Fine S
Cancer Chemother Pharmacol; 1987; 19(1):75-9. PubMed ID: 3815729
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of intra-arterial and intravenous cisplatin in head and neck cancer patients.
Gouyette A; Apchin A; Foka M; Richard JM
Eur J Cancer Clin Oncol; 1986 Mar; 22(3):257-63. PubMed ID: 3709595
[TBL] [Abstract][Full Text] [Related]
9. [Effective treatment of peritoneal carcinosis by intraperitoneal cis-diamminedichloroplatinum (c-DDP) administration with systemic sodium thiosulfate protection. Clinical results and pharmacokinetics].
Rückle H; Ehninger G; Jakob F; Wilms K
Klin Wochenschr; 1986 May; 64(10):467-74. PubMed ID: 3723994
[TBL] [Abstract][Full Text] [Related]
10. Concentrations of cisplatin and doxorubicin in ascites and peritoneal tumor nodules before and after pressurized intraperitoneal aerosol chemotherapy (PIPAC) in patients with peritoneal metastasis.
Tempfer CB; Hilal Z; Dogan A; Petersen M; Rezniczek GA
Eur J Surg Oncol; 2018 Jul; 44(7):1112-1117. PubMed ID: 29753612
[TBL] [Abstract][Full Text] [Related]
11. [Pharmacokinetic study of intraperitoneal chemotherapy with high-dose cisplatin for advanced ovarian cancer].
Deng C; Huang R; Lian L
Zhonghua Fu Chan Ke Za Zhi; 1996 Mar; 31(3):159-62. PubMed ID: 8758790
[TBL] [Abstract][Full Text] [Related]
12. Penetration of carboplatin and cisplatin into rat peritoneal tumor nodules after intraperitoneal chemotherapy.
Los G; Verdegaal EM; Mutsaers PH; McVie JG
Cancer Chemother Pharmacol; 1991; 28(3):159-65. PubMed ID: 1855272
[TBL] [Abstract][Full Text] [Related]
13. Cisplatin administered as a continuous 5-day infusion: plasma platinum levels and urine platinum excretion.
Belliveau JF; Posner MR; Ferrari L; Crabtree GW; Cummings FJ; Wiemann MC; O'Leary GP; Griffin H; Phaneuf MA; O'Rourke A
Cancer Treat Rep; 1986 Oct; 70(10):1215-7. PubMed ID: 3756943
[TBL] [Abstract][Full Text] [Related]
14. Clinical pharmacokinetics of carboplatin.
Oguri S; Sakakibara T; Mase H; Shimizu T; Ishikawa K; Kimura K; Smyth RD
J Clin Pharmacol; 1988 Mar; 28(3):208-15. PubMed ID: 3283185
[TBL] [Abstract][Full Text] [Related]
15. Reduced ability to clear ultrafilterable platinum with repeated courses of cisplatin.
Reece PA; Stafford I; Russell J; Gill PG
J Clin Oncol; 1986 Sep; 4(9):1392-8. PubMed ID: 3746376
[TBL] [Abstract][Full Text] [Related]
16. Serum and intraperitoneal pharmacokinetics of cisplatin within intraoperative intraperitoneal chemotherapy: influence of protein binding.
Royer B; Guardiola E; Polycarpe E; Hoizey G; Delroeux D; Combe M; Chaigneau L; Samain E; Chauffert B; Heyd B; Kantelip JP; Pivot X
Anticancer Drugs; 2005 Oct; 16(9):1009-16. PubMed ID: 16162978
[TBL] [Abstract][Full Text] [Related]
17. Test dose-guided administration of cisplatin in an anephric patient: a case report.
Ribrag V; Droz JP; Morizet J; Leclercq B; Gouyette A; Chabot GG
Ann Oncol; 1993 Sep; 4(8):679-82. PubMed ID: 8240999
[TBL] [Abstract][Full Text] [Related]
18. Tumor-tissue and plasma concentrations of platinum during chemotherapy of non-small-cell lung cancer patients.
Pujol JL; Cupissol D; Gestin-Boyer C; Bres J; Serrou B; Michel FB
Cancer Chemother Pharmacol; 1990; 27(1):72-5. PubMed ID: 2173980
[TBL] [Abstract][Full Text] [Related]
19. Phase I clinical and pharmacological study of intraperitoneal cis-bis-neodecanoato( trans- R, R-1, 2-diaminocyclohexane)-platinum II entrapped in multilamellar liposome vesicles.
Verschraegen CF; Kumagai S; Davidson R; Feig B; Mansfield P; Lee SJ; Maclean DS; Hu W; Khokhar AR; Siddik ZH
J Cancer Res Clin Oncol; 2003 Oct; 129(10):549-55. PubMed ID: 14513369
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic evidence for an enterohepatic circulation in a patient treated with cis-dichlorodiammineplatinum (II).
Vermorken JB; van der Vijgh WJ; Pinedo HM
Res Commun Chem Pathol Pharmacol; 1980 May; 28(2):319-28. PubMed ID: 7190316
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
